Cargando…
Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025208/ https://www.ncbi.nlm.nih.gov/pubmed/36538061 http://dx.doi.org/10.1007/s00262-022-03351-w |
| _version_ | 1784909276823683072 |
|---|---|
| author | Weber, Jeffrey S. Poretta, Tayla Stwalley, Brian D. Sakkal, Leon A. Du, Ella X. Wang, Travis Chen, Yan Wang, Yan Betts, Keith A. Shoushtari, Alexander N. |
| author_facet | Weber, Jeffrey S. Poretta, Tayla Stwalley, Brian D. Sakkal, Leon A. Du, Ella X. Wang, Travis Chen, Yan Wang, Yan Betts, Keith A. Shoushtari, Alexander N. |
| author_sort | Weber, Jeffrey S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10025208 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100252082023-03-21 Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival Weber, Jeffrey S. Poretta, Tayla Stwalley, Brian D. Sakkal, Leon A. Du, Ella X. Wang, Travis Chen, Yan Wang, Yan Betts, Keith A. Shoushtari, Alexander N. Cancer Immunol Immunother Correction Springer Berlin Heidelberg 2022-12-20 2023 /pmc/articles/PMC10025208/ /pubmed/36538061 http://dx.doi.org/10.1007/s00262-022-03351-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Weber, Jeffrey S. Poretta, Tayla Stwalley, Brian D. Sakkal, Leon A. Du, Ella X. Wang, Travis Chen, Yan Wang, Yan Betts, Keith A. Shoushtari, Alexander N. Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival |
| title | Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival |
| title_full | Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival |
| title_fullStr | Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival |
| title_full_unstemmed | Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival |
| title_short | Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival |
| title_sort | correction to: nivolumab versus placebo as adjuvant therapy for resected stage iii melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025208/ https://www.ncbi.nlm.nih.gov/pubmed/36538061 http://dx.doi.org/10.1007/s00262-022-03351-w |
| work_keys_str_mv | AT weberjeffreys correctiontonivolumabversusplaceboasadjuvanttherapyforresectedstageiiimelanomaapropensityweightedindirecttreatmentcomparisonandnumberneededtotreatanalysisforrecurrencefreesurvivalandoverallsurvival AT porettatayla correctiontonivolumabversusplaceboasadjuvanttherapyforresectedstageiiimelanomaapropensityweightedindirecttreatmentcomparisonandnumberneededtotreatanalysisforrecurrencefreesurvivalandoverallsurvival AT stwalleybriand correctiontonivolumabversusplaceboasadjuvanttherapyforresectedstageiiimelanomaapropensityweightedindirecttreatmentcomparisonandnumberneededtotreatanalysisforrecurrencefreesurvivalandoverallsurvival AT sakkalleona correctiontonivolumabversusplaceboasadjuvanttherapyforresectedstageiiimelanomaapropensityweightedindirecttreatmentcomparisonandnumberneededtotreatanalysisforrecurrencefreesurvivalandoverallsurvival AT duellax correctiontonivolumabversusplaceboasadjuvanttherapyforresectedstageiiimelanomaapropensityweightedindirecttreatmentcomparisonandnumberneededtotreatanalysisforrecurrencefreesurvivalandoverallsurvival AT wangtravis correctiontonivolumabversusplaceboasadjuvanttherapyforresectedstageiiimelanomaapropensityweightedindirecttreatmentcomparisonandnumberneededtotreatanalysisforrecurrencefreesurvivalandoverallsurvival AT chenyan correctiontonivolumabversusplaceboasadjuvanttherapyforresectedstageiiimelanomaapropensityweightedindirecttreatmentcomparisonandnumberneededtotreatanalysisforrecurrencefreesurvivalandoverallsurvival AT wangyan correctiontonivolumabversusplaceboasadjuvanttherapyforresectedstageiiimelanomaapropensityweightedindirecttreatmentcomparisonandnumberneededtotreatanalysisforrecurrencefreesurvivalandoverallsurvival AT bettskeitha correctiontonivolumabversusplaceboasadjuvanttherapyforresectedstageiiimelanomaapropensityweightedindirecttreatmentcomparisonandnumberneededtotreatanalysisforrecurrencefreesurvivalandoverallsurvival AT shoushtarialexandern correctiontonivolumabversusplaceboasadjuvanttherapyforresectedstageiiimelanomaapropensityweightedindirecttreatmentcomparisonandnumberneededtotreatanalysisforrecurrencefreesurvivalandoverallsurvival |